Skip to Main Content

Tara Sanft, MD

Associate Professor of Medicine (Medical Oncology); Chief, Patient Experience Officer; Medical Director, Survivorship Clinic

Contact Information

Tara Sanft, MD

Mailing Address

  • Medical Oncology

    PO Box 208032

    New Haven, CT, 06520-8032

    United States

Research Summary

I am director of the Adult Survivorship Program at Yale Cancer Center and an associate professor in medicine. I treat women diagnosed with breast cancer and I oversee a weekly survivorship clinic that provides comprehensive consultations to adult cancer survivors regarding medical care, coping, and lifestyle recommendations. In addition, I conduct a long-term breast cancer survivor clinic where I see women who are > 5 years from diagnosis and no longer on active treatment. I conduct research with Dr. Melinda Irwin, and have completed several lifestyle intervention trials. I am now the Principal Investigator for an R01-funded study in which I am overseeing recruitment from our oncology clinics and working with the research team to conduct the intervention. Additionally, I am the site Principal Investigator of a study looking a resilience trajectories in patients diagnosed with breast, colon and prostate cancer, so that we may better learn who needs our help the most in order to thrive after cancer. I have growing interest in the field of communication in healthcare and intend to study the impact communication skills training has on providers and patients.

Extensive Research Description

I am director of the Adult Survivorship Program at Yale Cancer Center and an associate professor in medicine. I treat women diagnosed with breast cancer and I oversee a weekly survivorship clinic that provides comprehensive consultations to adult cancer survivors regarding medical care and lifestyle recommendations. In addition, I conduct a long-term breast cancer survivor clinic where I see women who are > 5 years from diagnosis and no longer on active treatment. I conduct research with Dr. Melinda Irwin, and have completed several lifestyle intervention trials. I am now the Principal Investigator for an R01-funded study in which I am overseeing recruitment from our oncology clinics and working with the research team to conduct the intervention. Additionally, I am the site Principal Investigator of a study looking a resilience trajectories in patients diagnosed with breast, colon and prostate cancer, so that we may better learn who needs our help the most in order to thrive after cancer.

Research Interests

Breast Diseases

Clinical Trials

ConditionsStudy Title
BreastA Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
BreastA Phase I, Open-Label Study of D-0502 Single Agent and D-0502 in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer
Breast - Female; BreastTAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
Breast - Female; Breast - Male; BreastA Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Breast - Female; BreastA Randomized Phase II Study to Evaluate Efficacy of T-DM1 With or Without Palbociclib in the Treatment of Patients With Metastatic HER2 Positive Breast Cancer
BreastRandomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer
Breast - Female; Phase IA Phase II Multiple-Arm, Open-Label, Randomized Study of PARP Inhibition (Veliparib; ABT-888) and Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) Either Alone or in Combination in Homologous DNA Repair (HDR) Deficient Triple Negative Breast Cancer (TNBC)
Breast - Female; Breast - MaleA Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Breast - Female; Breast - MaleA Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer